Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

Israeli cybersecurity companies, which account for 7% of all tech companies in Israel, raised $3.8 billion last year — about ...

Teva Pharmaceutical collaborates with Klinge Biopharma and Formycon AG to commercialize Formycon's biosimilar candidate to ...

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

Under the terms of the agreement, Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name AHZANTIVE®3, subject to regulatory approval.

Commenting on the agreement, Nicola Mikulcik, CBO of Formycon, says, “With Teva, we are gaining a strong and proven partner for FYB203 in the major parts of Europe and Israel. Teva is already ...

New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.

(NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of ...

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has ...

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

(NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of ...